Vascular & Endovascular

This channel includes news on non-coronary vascular disease and therapies. These include peripheral artery disease (PAD), abdominal and thoracic aortic aneurysm (AAA and TAA), aortic dissection, pulmonary embolism (PE), critical limb ischemia (CLI), carotid artery and stroke interventions, venous interventions, deep vein thrombosis (DVT), and interventional radiology therapies. The focus on most of these therapies is minimally invasive, catheter-based procedures performed in a cath lab.

Thumbnail

How to diagnose and treat rare blood clots associated with a COVID-19 vaccine

The team behind the new guidance also emphasized how important it still is for all adults to get vaccinated. 

FDA authorizes brain-computer interface for stroke patients

The FDA has also indicated it is “establishing special controls for devices of this type,” including labeling and testing requirements.

Thumbnail

‘The next wave of complications’: Asymptomatic COVID-19 patients face a prolonged stroke risk

The median time from a positive serological test result to acute ischemic stroke was nearly 55 days. 

Thumbnail

How patient care changes when stroke centers offer endovascular thrombectomy

Researchers simulated more than 80 million patient encounters, running a variety of models to gain as much insight as possible. 

Thumbnail

USPSTF shares recommendation on screening asymptomatic adults for atrial fibrillation

The organization is accepting public comments on this topic until May 17.

US recommends pause of Johnson & Johnson COVID-19 vaccine due to blood clot risk

The FDA and CDC announced the recommendation in a new joint statement. Nearly 7 million doses of the Johnson & Johnson vaccine have been administered in the United States so far. 

Johnson & Johnson COVID-19 vaccine being investigated for possible blood clot risk

The European Medicines Agency is investigating the issue with help from the FDA. At this stage, the group emphasized that it remains unclear if the Johnson & Johnson vaccine is associated with any specific blood clot risk.

AstraZeneca COVID-19 vaccine associated with risk of rare, potentially fatal blood clots

These blood clots have been responsible for a total of 18 deaths. Experts have continued to emphasize that the benefits of vaccination still outweigh the risks.